Health Care & Life Sciences » Pharmaceuticals | Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
17.00
36.00
96.00
206.00
64.00
54
Gross Income
17.00
36.00
96.00
206.00
64.00
54
SG&A Expense
10,871.00
27,620.00
48,066.00
40,363.00
21,227.00
26,268
EBIT
10,888.00
27,656.00
48,162.00
40,569.00
21,291.00
26,322
Unusual Expense
-
-
-
73.00
6.00
-
Non Operating Income/Expense
-
-
-
54.00
162.00
233
Pretax Income
10,884.00
27,616.00
48,054.00
40,442.00
21,123.00
26,089
Income Tax
-
-
-
1,600.00
-
-
Consolidated Net Income
10,884.00
27,616.00
48,054.00
38,842.00
21,123.00
26,089
Net Income
10,884.00
27,616.00
48,054.00
38,842.00
21,123.00
26,089
Net Income After Extraordinaries
10,884.00
27,616.00
48,054.00
38,842.00
21,123.00
26,089
Net Income Available to Common
10,884.00
27,616.00
48,054.00
38,842.00
21,123.00
29,355
EPS (Basic)
33.70
27.70
28.60
15.41
3.17
9.03
Basic Shares Outstanding
323.10
998.60
1,679.10
2,521.00
6,665.10
3,252
EPS (Diluted)
33.68
27.66
28.62
15.41
3.17
9.03
Diluted Shares Outstanding
323.10
998.60
1,679.10
2,521.00
6,665.10
3,252
EBITDA
10,871.00
27,620.00
48,066.00
40,363.00
21,227.00
26,268
Non-Operating Interest Income
4.00
40.00
108.00
-
-
-

About Tonix Pharmaceuticals Holding

View Profile
Address
509 Madison Avenue
New York New York 10022
United States
Employees -
Website http://www.tonixpharma.com
Updated 07/08/2019
Tonix Pharmaceuticals Holding Corp. operates as a clinical-stage pharmaceutical company, which engages in the development of pharmaceutical products for public health challenges. It focuses on delivering an efficacious, and safe long-term treatment for posttraumatic stress disorder. It offers TNX-102 SL, TNX-601, TNX-801, TNX-301, and TNX-701.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.